Incretins and their influence on the course of type 2 diabetes in patients with morbid obesity after bariatric oper
https://doi.org/10.14341/omet201223-10
Abstract
References
1. Яшков ЮИ. Эффективность хирургических методов лечения ожирения при сахарном диабете II типа. Хирургия 2000;12:49-54.
2. Вaggio L, Drucker D. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57.
3. Bailey C, Wilkes L, Conlon J. et al. Effects of gastric inhibitory polypeptide, vasoactive intestinal polypeptide and peptide histidine isoleucine on the secretion of hormones by isolated mouse pancreatic islets. J Endocrinology 1990;125:375-79.
4. Bayliss W, Starling E. The mechanism of pancreatic secretion. J Physiol 1902;28:325-53.
5. Bollag R, Zhong Q, Ding K. et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol 2001;177:35-41.
6. Brown J, Dryburgh J. Gastric Inhibitory Polypeptide. II. The complete amino acid sequence. Can. J. Biochem 1971;49:867-72.
7. Buchwald H, Avidor Y, Braunwald E. et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724-37.
8. Buchwald H, Estok R, Fahrbach K. et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007;142:621-32.
9. Buchwald H, Estok R, Fahrbach K. et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:249-61.
10. Buchwald H, Varco R. Metabolic Surgery. New York: Grune & Stratton 1978. chap 11.
11. Сummings D, Overduin J, Foster-Schubert K. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004;89:2608-15.
12. Drucker D. The biology of incretin hormones. Сell Metabolism 2006;3:153-65.
13. Drucker D. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32.
14. Ehses J, Casilla V, Doty T. et al. Glucose-dependent insulinotropic polypeptide promotes beta-cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p-38 mitigen-activated protein kinase. Endocrinology 2003;144:4433-45.
15. Elrick H, Stimmler L, Hlad C, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-82.
16. Holst J, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-Е206.
17. Holst J, Vislboll T, Deacon C. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-36.
18. Kim W, Egan J. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008;60:470-512.
19. Laferrere B, Heshka S, Wang K et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007;30:1709-16.
20. MacDonald K, Long S, Swanson M et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997;1:213-20.
21. Mason E. The mechanism of type 2 diabetes. Obes Surg 2005;15:459-61.
22. Moore B, Edie E, Abram J. On the treatment of diabetes mellitus by acid extract of duodenal mucosa membrane. Biochem J 1906;1:28-38.
23. Naslund E, Bogefors J, Skogar S et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999;277:R910-16.
24. Nauck M. Unraveling the science of incretin biology. Am J Med 2009;122:S3-S10.
25. Nauck M, Kleine N, Űrskov C. et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-44.
26. Nauck M, Stockmann F, Ebert R. et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52.
27. Neumiller J. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assos 2009;49(1):S16-29.
28. Nikolaidis L, Mankad S, Sokos G et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109(8):962-65.
29. Perfetti R. The role of GLP-1 in the regulation of the islet cell mass. Medscape Diabet Endocrinol 2004;6(2):134-38.
30. Perley M, Kipins D. Plasma insulin responces to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967;46:1954-62.
31. Pories W. Prevention and control of type 2 diabetes mellitus with gastric bypass surgery. International J Obesity 1998;22:S85.
32. Pories W. Remission of type 2 diabetes mellitus following the gastric bypass operation: timing and magnitude of weight loss. Progress in obesity research: 8, Edited by B.Guy-Grand and G. Ailhaud Lohn Libbey & Company Ltd. 8th Internatuional Congress on Obesity 1999:511-16.
33. Pories W, Caro J, Flickinger E et al. The control of diabetes mellitus in the morbidly obese with the Greenville Gastric Bypass. Ann Surg 1987;206:316-23.
34. Pories W, Dohm G. Full and Durable Remission of Type 2 Diabetes? Through Surgery? Surg Obes Relat Dis 2009;5(2):285-88.
35. Pories W, MacDonald K, Flickinger E et al. Is type II diabetes mellitus a surgical disease? Ann Surg 1992;215(6):633-42.
36. Pories W, Swanson M, MacDonald K et al. Who would have thought it? An operation proves to be the most effective therapy for adult onset diabetes mellitus. Ann Surg 1995;222:339-52.
37. Ranganath L. The enteroinsular axis: implications for human metabolism. Clin Chem Lab Med 2008;46:43-56.
38. Rodieux F, Giusti V, D' Alessio D et al. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring) 2008;16:298-305.
39. le Roux C, Welbourn R, Werling M et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Annals of Surgery 2007;246(5):780-85.
40. Rubino F, Gagner M. Potencial of surgery for curing type 2 diabetes mellitus. Ann Surg 2002;236:554-59.
41. Salinari S, Bertuzzi A, Asnaghi S et al. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care 2009;32:375-80.
42. Schmidt W, Siegel E, Creutzfeld W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985;28:704-7.
43. Scopinaro N, Papadia F, Camerini G et al. A comparison of a personal series of biliopancreatic diversion and literature data on gastric bypass help to explain the mechanisms of resolution of type 2 diabetes by the two operations. Obes Surg 2008;18:1035-38.
44. Sjostrom L, Lindroos A, Peltonen M et al. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Eng J Med 2004;351: 2683-93.
45. Toft-Nielsen M, Damholt M, Madsbad S et al. Determinats of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-23.
46. Vilsboll T, Krarup T, Deacon C et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-13.
47. Wideman R, Kieffer T. Glucose-dependent insulinotropic polypeptide as a regulator of beta cell function and fate. Hormone and metabolic research 2004;36:782-86.
Review
For citations:
, , Incretins and their influence on the course of type 2 diabetes in patients with morbid obesity after bariatric oper. Obesity and metabolism. 2012;9(2):3-10. (In Russ.) https://doi.org/10.14341/omet201223-10

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).